Meeting
Abstract Number: 339
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Currently, once-daily nebulized bronchodilator therapy is unavailable for patients with chronic obstructive pulmonary disease (COPD). Prior studies demonstrated that once-daily revefenacin (REV) doses of 88 and 175 µg produced significant bronchodilation in COPD patients. We report the pooled results of two replicate phase 3 efficacy trials. Methods: In these double-blind, placebo-controlled, parallel-group, 12-week trials […]